Published on
September 19, 2020
- 11:30 GMT
Phase 3 NORA data of ZEJULA® (niraparib) demonstrate significant PFS benefit, regardless of biomarker status, with an improved ...
The NORA study, presented as a late-breaker oral presentation at the European Society for Medical Oncology (ESMO) 2020 Virtual Congress, demonstrates that niraparib maintenance treatment resulted in a 68% reduction in the risk of disease progression or …
Distribution channels:
